Free Trial
NASDAQ:INM

InMed Pharmaceuticals Q2 2024 Earnings Report

InMed Pharmaceuticals logo
$2.99 +0.01 (+0.47%)
As of 12:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InMed Pharmaceuticals EPS Results

Actual EPS
-$3.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

InMed Pharmaceuticals Revenue Results

Actual Revenue
$1.24 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

InMed Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, February 13, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

InMed Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

InMed Pharmaceuticals Earnings Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
See More InMed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like InMed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMed Pharmaceuticals and other key companies, straight to your email.

About InMed Pharmaceuticals

InMed Pharmaceuticals (NASDAQ:INM), a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

View InMed Pharmaceuticals Profile

More Earnings Resources from MarketBeat